nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—SRMS—liver cancer	0.183	0.428	CbGaD
Bosutinib—TNK2—liver cancer	0.183	0.428	CbGaD
Bosutinib—MAP3K7—Sorafenib—liver cancer	0.0773	0.227	CbGbCtD
Bosutinib—ABL1—liver cancer	0.062	0.145	CbGaD
Bosutinib—HIPK4—Sorafenib—liver cancer	0.0494	0.145	CbGbCtD
Bosutinib—CSF1R—Sorafenib—liver cancer	0.0444	0.13	CbGbCtD
Bosutinib—STK10—Sorafenib—liver cancer	0.0444	0.13	CbGbCtD
Bosutinib—MAP2K5—Sorafenib—liver cancer	0.0404	0.119	CbGbCtD
Bosutinib—PDGFRB—Sorafenib—liver cancer	0.0404	0.119	CbGbCtD
Bosutinib—MAP3K19—Sorafenib—liver cancer	0.0371	0.109	CbGbCtD
Bosutinib—ABCB1—Sorafenib—liver cancer	0.00264	0.00777	CbGbCtD
Bosutinib—Acute lymphocytic leukaemia—Epirubicin—liver cancer	0.00258	0.0486	CcSEcCtD
Bosutinib—Acute lymphocytic leukaemia—Doxorubicin—liver cancer	0.00239	0.045	CcSEcCtD
Bosutinib—Abdominal tenderness—Sorafenib—liver cancer	0.00231	0.0434	CcSEcCtD
Bosutinib—Lipase increased—Sorafenib—liver cancer	0.00198	0.0373	CcSEcCtD
Bosutinib—Abdominal pain lower—Sorafenib—liver cancer	0.00183	0.0345	CcSEcCtD
Bosutinib—ABCB1—Doxorubicin—liver cancer	0.0016	0.00471	CbGbCtD
Bosutinib—CYP3A4—Sorafenib—liver cancer	0.00158	0.00465	CbGbCtD
Bosutinib—SRMS—gall bladder—liver cancer	0.00154	0.0423	CbGeAlD
Bosutinib—STK26—gall bladder—liver cancer	0.00145	0.0399	CbGeAlD
Bosutinib—Gastrointestinal toxicity—Epirubicin—liver cancer	0.00131	0.0247	CcSEcCtD
Bosutinib—Amylase increased—Sorafenib—liver cancer	0.00122	0.023	CcSEcCtD
Bosutinib—Gastrointestinal toxicity—Doxorubicin—liver cancer	0.00121	0.0228	CcSEcCtD
Bosutinib—Hypophosphataemia—Sorafenib—liver cancer	0.001	0.0189	CcSEcCtD
Bosutinib—CYP3A4—Doxorubicin—liver cancer	0.00096	0.00282	CbGbCtD
Bosutinib—CDK2—embryo—liver cancer	0.000928	0.0255	CbGeAlD
Bosutinib—Pleural effusion—Sorafenib—liver cancer	0.000761	0.0143	CcSEcCtD
Bosutinib—ALK—embryo—liver cancer	0.000739	0.0203	CbGeAlD
Bosutinib—Vandetanib—ABL1—liver cancer	0.000715	0.305	CrCbGaD
Bosutinib—ERBB4—embryo—liver cancer	0.000691	0.019	CbGeAlD
Bosutinib—ROCK1—embryo—liver cancer	0.000682	0.0188	CbGeAlD
Bosutinib—EPHB3—embryo—liver cancer	0.000657	0.0181	CbGeAlD
Bosutinib—Blood bilirubin increased—Sorafenib—liver cancer	0.000616	0.0116	CcSEcCtD
Bosutinib—MAP2K1—embryo—liver cancer	0.000616	0.0169	CbGeAlD
Bosutinib—CSK—embryo—liver cancer	0.000612	0.0168	CbGeAlD
Bosutinib—Vandetanib—KDR—liver cancer	0.000608	0.259	CrCbGaD
Bosutinib—Rash papular—Epirubicin—liver cancer	0.000578	0.0109	CcSEcCtD
Bosutinib—PTK2B—embryo—liver cancer	0.000572	0.0157	CbGeAlD
Bosutinib—EPHA4—embryo—liver cancer	0.000549	0.0151	CbGeAlD
Bosutinib—ERBB3—embryo—liver cancer	0.000543	0.0149	CbGeAlD
Bosutinib—Rash papular—Doxorubicin—liver cancer	0.000535	0.0101	CcSEcCtD
Bosutinib—Drug hypersensitivity—Epirubicin—liver cancer	0.000535	0.0101	CcSEcCtD
Bosutinib—PTK2—embryo—liver cancer	0.000527	0.0145	CbGeAlD
Bosutinib—Pericardial effusion—Epirubicin—liver cancer	0.000525	0.00987	CcSEcCtD
Bosutinib—Vandetanib—VEGFA—liver cancer	0.000515	0.22	CrCbGaD
Bosutinib—PDGFRB—gall bladder—liver cancer	0.000512	0.0141	CbGeAlD
Bosutinib—TLK1—liver—liver cancer	0.00051	0.014	CbGeAlD
Bosutinib—RPS6KB1—embryo—liver cancer	0.000507	0.0139	CbGeAlD
Bosutinib—FGR—embryo—liver cancer	0.000504	0.0139	CbGeAlD
Bosutinib—PRKCQ—liver—liver cancer	0.000502	0.0138	CbGeAlD
Bosutinib—Pericarditis—Epirubicin—liver cancer	0.000498	0.00936	CcSEcCtD
Bosutinib—SIK2—liver—liver cancer	0.000496	0.0136	CbGeAlD
Bosutinib—Drug hypersensitivity—Doxorubicin—liver cancer	0.000495	0.0093	CcSEcCtD
Bosutinib—Pericardial effusion—Doxorubicin—liver cancer	0.000486	0.00913	CcSEcCtD
Bosutinib—Hepatic function abnormal—Sorafenib—liver cancer	0.000484	0.0091	CcSEcCtD
Bosutinib—FRK—liver—liver cancer	0.000483	0.0133	CbGeAlD
Bosutinib—CLK3—liver—liver cancer	0.000471	0.013	CbGeAlD
Bosutinib—FYN—embryo—liver cancer	0.00047	0.0129	CbGeAlD
Bosutinib—CASK—liver—liver cancer	0.000461	0.0127	CbGeAlD
Bosutinib—Pericarditis—Doxorubicin—liver cancer	0.000461	0.00866	CcSEcCtD
Bosutinib—Myelosuppression—Epirubicin—liver cancer	0.000459	0.00863	CcSEcCtD
Bosutinib—Renal failure acute—Sorafenib—liver cancer	0.000458	0.00861	CcSEcCtD
Bosutinib—EIF2AK1—liver—liver cancer	0.000456	0.0125	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Epirubicin—liver cancer	0.000442	0.196	CbGdCrCtD
Bosutinib—FES—liver—liver cancer	0.000442	0.0122	CbGeAlD
Bosutinib—VRK2—liver—liver cancer	0.000442	0.0122	CbGeAlD
Bosutinib—TNIK—liver—liver cancer	0.000433	0.0119	CbGeAlD
Bosutinib—CDK2—liver—liver cancer	0.000429	0.0118	CbGeAlD
Bosutinib—STK26—liver—liver cancer	0.000425	0.0117	CbGeAlD
Bosutinib—Myelosuppression—Doxorubicin—liver cancer	0.000425	0.00799	CcSEcCtD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—liver cancer	0.000409	0.181	CbGdCrCtD
Bosutinib—SRC—embryo—liver cancer	0.000408	0.0112	CbGeAlD
Bosutinib—WEE1—liver—liver cancer	0.000407	0.0112	CbGeAlD
Bosutinib—DMPK—liver—liver cancer	0.000407	0.0112	CbGeAlD
Bosutinib—Dehydration—Sorafenib—liver cancer	0.000393	0.0074	CcSEcCtD
Bosutinib—STK25—liver—liver cancer	0.000389	0.0107	CbGeAlD
Bosutinib—Abdominal pain upper—Sorafenib—liver cancer	0.000386	0.00726	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.000381	0.00716	CcSEcCtD
Bosutinib—PLK2—liver—liver cancer	0.000378	0.0104	CbGeAlD
Bosutinib—Nasopharyngitis—Sorafenib—liver cancer	0.000378	0.00711	CcSEcCtD
Bosutinib—SIK3—liver—liver cancer	0.000376	0.0103	CbGeAlD
Bosutinib—Gastritis—Sorafenib—liver cancer	0.000374	0.00704	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Sorafenib—liver cancer	0.000373	0.00701	CcSEcCtD
Bosutinib—Hypophosphataemia—Epirubicin—liver cancer	0.00037	0.00697	CcSEcCtD
Bosutinib—CSF1R—embryo—liver cancer	0.000366	0.0101	CbGeAlD
Bosutinib—STK4—liver—liver cancer	0.000362	0.00995	CbGeAlD
Bosutinib—Febrile neutropenia—Epirubicin—liver cancer	0.000358	0.00673	CcSEcCtD
Bosutinib—CAMK1D—liver—liver cancer	0.000357	0.00983	CbGeAlD
Bosutinib—STK24—liver—liver cancer	0.000353	0.00972	CbGeAlD
Bosutinib—Abdominal discomfort—Sorafenib—liver cancer	0.00035	0.00659	CcSEcCtD
Bosutinib—Hypophosphataemia—Doxorubicin—liver cancer	0.000343	0.00645	CcSEcCtD
Bosutinib—Neutropenia—Sorafenib—liver cancer	0.000342	0.00643	CcSEcCtD
Bosutinib—FER—liver—liver cancer	0.000342	0.0094	CbGeAlD
Bosutinib—LYN—liver—liver cancer	0.00034	0.00935	CbGeAlD
Bosutinib—BTK—liver—liver cancer	0.000333	0.00917	CbGeAlD
Bosutinib—Febrile neutropenia—Doxorubicin—liver cancer	0.000331	0.00623	CcSEcCtD
Bosutinib—TNK2—liver—liver cancer	0.000328	0.00903	CbGeAlD
Bosutinib—Pneumonia—Sorafenib—liver cancer	0.000328	0.00616	CcSEcCtD
Bosutinib—Infestation NOS—Sorafenib—liver cancer	0.000326	0.00613	CcSEcCtD
Bosutinib—Infestation—Sorafenib—liver cancer	0.000326	0.00613	CcSEcCtD
Bosutinib—PDGFRB—embryo—liver cancer	0.000325	0.00893	CbGeAlD
Bosutinib—MAP4K2—liver—liver cancer	0.000324	0.00891	CbGeAlD
Bosutinib—Renal failure—Sorafenib—liver cancer	0.00032	0.00602	CcSEcCtD
Bosutinib—STK3—liver—liver cancer	0.000319	0.00879	CbGeAlD
Bosutinib—ROCK1—liver—liver cancer	0.000315	0.00867	CbGeAlD
Bosutinib—Hepatobiliary disease—Sorafenib—liver cancer	0.000308	0.0058	CcSEcCtD
Bosutinib—BMPR2—liver—liver cancer	0.000306	0.00843	CbGeAlD
Bosutinib—STK36—liver—liver cancer	0.000304	0.00836	CbGeAlD
Bosutinib—MERTK—liver—liver cancer	0.0003	0.00826	CbGeAlD
Bosutinib—MAP4K4—liver—liver cancer	0.000295	0.00811	CbGeAlD
Bosutinib—NUAK2—liver—liver cancer	0.000293	0.00805	CbGeAlD
Bosutinib—BCR—liver—liver cancer	0.000293	0.00805	CbGeAlD
Bosutinib—MAP3K12—liver—liver cancer	0.000291	0.008	CbGeAlD
Bosutinib—ABL1—embryo—liver cancer	0.000289	0.00796	CbGeAlD
Bosutinib—Urinary tract disorder—Sorafenib—liver cancer	0.000289	0.00543	CcSEcCtD
Bosutinib—Connective tissue disorder—Sorafenib—liver cancer	0.000288	0.00541	CcSEcCtD
Bosutinib—Urethral disorder—Sorafenib—liver cancer	0.000287	0.00539	CcSEcCtD
Bosutinib—MAP2K1—liver—liver cancer	0.000285	0.00783	CbGeAlD
Bosutinib—STK35—liver—liver cancer	0.000285	0.00783	CbGeAlD
Bosutinib—CSK—liver—liver cancer	0.000283	0.00778	CbGeAlD
Bosutinib—Pleural effusion—Epirubicin—liver cancer	0.000281	0.00529	CcSEcCtD
Bosutinib—CSNK1A1—liver—liver cancer	0.000281	0.00773	CbGeAlD
Bosutinib—HCK—liver—liver cancer	0.000279	0.00768	CbGeAlD
Bosutinib—CLK1—liver—liver cancer	0.000279	0.00768	CbGeAlD
Bosutinib—ABL2—liver—liver cancer	0.000277	0.00763	CbGeAlD
Bosutinib—Erythema multiforme—Sorafenib—liver cancer	0.000277	0.0052	CcSEcCtD
Bosutinib—BMP2K—liver—liver cancer	0.000274	0.00754	CbGeAlD
Bosutinib—CAMK2G—liver—liver cancer	0.000274	0.00754	CbGeAlD
Bosutinib—Tinnitus—Sorafenib—liver cancer	0.000273	0.00513	CcSEcCtD
Bosutinib—LRRK2—liver—liver cancer	0.000272	0.00747	CbGeAlD
Bosutinib—Cardiac disorder—Sorafenib—liver cancer	0.000272	0.00511	CcSEcCtD
Bosutinib—EGFR—liver—liver cancer	0.000271	0.00745	CbGeAlD
Bosutinib—PTK2B—liver—liver cancer	0.000265	0.00728	CbGeAlD
Bosutinib—Immune system disorder—Sorafenib—liver cancer	0.000264	0.00497	CcSEcCtD
Bosutinib—Mediastinal disorder—Sorafenib—liver cancer	0.000264	0.00496	CcSEcCtD
Bosutinib—CSNK1E—liver—liver cancer	0.00026	0.00716	CbGeAlD
Bosutinib—Pleural effusion—Doxorubicin—liver cancer	0.00026	0.00489	CcSEcCtD
Bosutinib—SIK1—liver—liver cancer	0.000256	0.00705	CbGeAlD
Bosutinib—IRAK4—liver—liver cancer	0.000256	0.00705	CbGeAlD
Bosutinib—Liver injury—Epirubicin—liver cancer	0.000256	0.00481	CcSEcCtD
Bosutinib—Malnutrition—Sorafenib—liver cancer	0.000255	0.00479	CcSEcCtD
Bosutinib—ERBB3—liver—liver cancer	0.000251	0.00691	CbGeAlD
Bosutinib—MAP2K2—liver—liver cancer	0.000251	0.0069	CbGeAlD
Bosutinib—ULK3—liver—liver cancer	0.000251	0.0069	CbGeAlD
Bosutinib—Dysgeusia—Sorafenib—liver cancer	0.000249	0.00469	CcSEcCtD
Bosutinib—MAP3K2—liver—liver cancer	0.000249	0.00685	CbGeAlD
Bosutinib—MAP3K7—liver—liver cancer	0.000247	0.00678	CbGeAlD
Bosutinib—TBK1—liver—liver cancer	0.000244	0.00671	CbGeAlD
Bosutinib—PTK2—liver—liver cancer	0.000244	0.00671	CbGeAlD
Bosutinib—IRAK1—liver—liver cancer	0.000239	0.00657	CbGeAlD
Bosutinib—Liver injury—Doxorubicin—liver cancer	0.000237	0.00445	CcSEcCtD
Bosutinib—Gefitinib—CYP1A1—liver cancer	0.000236	0.101	CrCbGaD
Bosutinib—Anaemia—Sorafenib—liver cancer	0.000235	0.00443	CcSEcCtD
Bosutinib—RPS6KB1—liver—liver cancer	0.000234	0.00645	CbGeAlD
Bosutinib—LCK—liver—liver cancer	0.000233	0.00641	CbGeAlD
Bosutinib—FGR—liver—liver cancer	0.000233	0.00641	CbGeAlD
Bosutinib—AXL—liver—liver cancer	0.000232	0.00639	CbGeAlD
Bosutinib—Leukopenia—Sorafenib—liver cancer	0.000228	0.00429	CcSEcCtD
Bosutinib—Blood bilirubin increased—Epirubicin—liver cancer	0.000228	0.00428	CcSEcCtD
Bosutinib—SLK—liver—liver cancer	0.000223	0.00615	CbGeAlD
Bosutinib—Cough—Sorafenib—liver cancer	0.000222	0.00418	CcSEcCtD
Bosutinib—EPHB4—liver—liver cancer	0.000222	0.0061	CbGeAlD
Bosutinib—EPHA2—liver—liver cancer	0.000218	0.00599	CbGeAlD
Bosutinib—FYN—liver—liver cancer	0.000217	0.00598	CbGeAlD
Bosutinib—Arthralgia—Sorafenib—liver cancer	0.000217	0.00408	CcSEcCtD
Bosutinib—Myalgia—Sorafenib—liver cancer	0.000217	0.00408	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000215	0.00405	CcSEcCtD
Bosutinib—MAP3K3—liver—liver cancer	0.000212	0.00584	CbGeAlD
Bosutinib—MAP4K5—liver—liver cancer	0.000212	0.00584	CbGeAlD
Bosutinib—Hyperkalaemia—Epirubicin—liver cancer	0.000212	0.00398	CcSEcCtD
Bosutinib—Blood bilirubin increased—Doxorubicin—liver cancer	0.000211	0.00396	CcSEcCtD
Bosutinib—Anaphylactic shock—Sorafenib—liver cancer	0.000208	0.00391	CcSEcCtD
Bosutinib—Infection—Sorafenib—liver cancer	0.000207	0.00388	CcSEcCtD
Bosutinib—Fluid retention—Epirubicin—liver cancer	0.000204	0.00384	CcSEcCtD
Bosutinib—Nervous system disorder—Sorafenib—liver cancer	0.000204	0.00383	CcSEcCtD
Bosutinib—Thrombocytopenia—Sorafenib—liver cancer	0.000204	0.00383	CcSEcCtD
Bosutinib—Skin disorder—Sorafenib—liver cancer	0.000202	0.0038	CcSEcCtD
Bosutinib—YES1—liver—liver cancer	0.000196	0.00539	CbGeAlD
Bosutinib—Hyperkalaemia—Doxorubicin—liver cancer	0.000196	0.00368	CcSEcCtD
Bosutinib—Rash maculo-papular—Epirubicin—liver cancer	0.000196	0.00368	CcSEcCtD
Bosutinib—STK10—liver—liver cancer	0.000194	0.00535	CbGeAlD
Bosutinib—TAOK3—liver—liver cancer	0.000194	0.00532	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000189	0.00356	CcSEcCtD
Bosutinib—Fluid retention—Doxorubicin—liver cancer	0.000189	0.00356	CcSEcCtD
Bosutinib—SRC—liver—liver cancer	0.000189	0.00519	CbGeAlD
Bosutinib—Dyspnoea—Sorafenib—liver cancer	0.000185	0.00348	CcSEcCtD
Bosutinib—Rash maculo-papular—Doxorubicin—liver cancer	0.000181	0.00341	CcSEcCtD
Bosutinib—Decreased appetite—Sorafenib—liver cancer	0.000181	0.0034	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Sorafenib—liver cancer	0.000179	0.00337	CcSEcCtD
Bosutinib—Fatigue—Sorafenib—liver cancer	0.000179	0.00337	CcSEcCtD
Bosutinib—Hepatic function abnormal—Epirubicin—liver cancer	0.000179	0.00336	CcSEcCtD
Bosutinib—Pain—Sorafenib—liver cancer	0.000178	0.00334	CcSEcCtD
Bosutinib—MAP2K5—liver—liver cancer	0.000173	0.00477	CbGeAlD
Bosutinib—Gastrointestinal pain—Sorafenib—liver cancer	0.00017	0.0032	CcSEcCtD
Bosutinib—CSF1R—liver—liver cancer	0.000169	0.00466	CbGeAlD
Bosutinib—Renal failure acute—Epirubicin—liver cancer	0.000169	0.00318	CcSEcCtD
Bosutinib—Hepatic function abnormal—Doxorubicin—liver cancer	0.000165	0.00311	CcSEcCtD
Bosutinib—Urticaria—Sorafenib—liver cancer	0.000165	0.00311	CcSEcCtD
Bosutinib—Abdominal pain—Sorafenib—liver cancer	0.000164	0.00309	CcSEcCtD
Bosutinib—Body temperature increased—Sorafenib—liver cancer	0.000164	0.00309	CcSEcCtD
Bosutinib—Renal impairment—Epirubicin—liver cancer	0.000164	0.00309	CcSEcCtD
Bosutinib—Renal failure acute—Doxorubicin—liver cancer	0.000157	0.00295	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000156	0.00294	CcSEcCtD
Bosutinib—Renal impairment—Doxorubicin—liver cancer	0.000152	0.00286	CcSEcCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—liver cancer	0.000151	0.067	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—liver cancer	0.000151	0.067	CbGdCrCtD
Bosutinib—Face oedema—Epirubicin—liver cancer	0.000151	0.00284	CcSEcCtD
Bosutinib—PDGFRB—liver—liver cancer	0.00015	0.00413	CbGeAlD
Bosutinib—Asthenia—Sorafenib—liver cancer	0.000149	0.0028	CcSEcCtD
Bosutinib—Pruritus—Sorafenib—liver cancer	0.000147	0.00277	CcSEcCtD
Bosutinib—Blood creatinine increased—Epirubicin—liver cancer	0.000146	0.00275	CcSEcCtD
Bosutinib—Dehydration—Epirubicin—liver cancer	0.000145	0.00273	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000145	0.00272	CcSEcCtD
Bosutinib—Abdominal pain upper—Epirubicin—liver cancer	0.000143	0.00268	CcSEcCtD
Bosutinib—Diarrhoea—Sorafenib—liver cancer	0.000142	0.00267	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000141	0.00265	CcSEcCtD
Bosutinib—Nasopharyngitis—Epirubicin—liver cancer	0.00014	0.00263	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—liver cancer	0.00014	0.062	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—liver cancer	0.00014	0.062	CbGdCrCtD
Bosutinib—Face oedema—Doxorubicin—liver cancer	0.00014	0.00263	CcSEcCtD
Bosutinib—Vandetanib—ALB—liver cancer	0.000138	0.0591	CrCbGaD
Bosutinib—Gastritis—Epirubicin—liver cancer	0.000138	0.0026	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000138	0.00259	CcSEcCtD
Bosutinib—Dizziness—Sorafenib—liver cancer	0.000137	0.00258	CcSEcCtD
Bosutinib—Blood creatinine increased—Doxorubicin—liver cancer	0.000135	0.00255	CcSEcCtD
Bosutinib—Influenza—Epirubicin—liver cancer	0.000135	0.00254	CcSEcCtD
Bosutinib—Dehydration—Doxorubicin—liver cancer	0.000134	0.00253	CcSEcCtD
Bosutinib—ABL1—liver—liver cancer	0.000134	0.00368	CbGeAlD
Bosutinib—Vomiting—Sorafenib—liver cancer	0.000132	0.00249	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—liver cancer	0.000132	0.00248	CcSEcCtD
Bosutinib—Gefitinib—ALB—liver cancer	0.000132	0.0561	CrCbGaD
Bosutinib—Rash—Sorafenib—liver cancer	0.000131	0.00246	CcSEcCtD
Bosutinib—Dermatitis—Sorafenib—liver cancer	0.000131	0.00246	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00013	0.00245	CcSEcCtD
Bosutinib—Headache—Sorafenib—liver cancer	0.00013	0.00245	CcSEcCtD
Bosutinib—Bronchitis—Epirubicin—liver cancer	0.00013	0.00244	CcSEcCtD
Bosutinib—Nasopharyngitis—Doxorubicin—liver cancer	0.000129	0.00243	CcSEcCtD
Bosutinib—Pancytopenia—Epirubicin—liver cancer	0.000128	0.00241	CcSEcCtD
Bosutinib—Gastritis—Doxorubicin—liver cancer	0.000128	0.00241	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000128	0.0024	CcSEcCtD
Bosutinib—Neutropenia—Epirubicin—liver cancer	0.000126	0.00238	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Epirubicin—liver cancer	0.000126	0.00236	CcSEcCtD
Bosutinib—Influenza—Doxorubicin—liver cancer	0.000125	0.00235	CcSEcCtD
Bosutinib—Nausea—Sorafenib—liver cancer	0.000123	0.00232	CcSEcCtD
Bosutinib—Pneumonia—Epirubicin—liver cancer	0.000121	0.00228	CcSEcCtD
Bosutinib—Infestation—Epirubicin—liver cancer	0.00012	0.00227	CcSEcCtD
Bosutinib—Infestation NOS—Epirubicin—liver cancer	0.00012	0.00227	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—liver cancer	0.00012	0.00226	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—liver cancer	0.000119	0.00223	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—liver cancer	0.000118	0.00223	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—liver cancer	0.000117	0.0022	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000116	0.00218	CcSEcCtD
Bosutinib—Hepatobiliary disease—Epirubicin—liver cancer	0.000114	0.00214	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—liver cancer	0.000112	0.00211	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—liver cancer	0.000112	0.00211	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—liver cancer	0.000111	0.0021	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—liver cancer	0.000111	0.0021	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—liver cancer	0.00011	0.049	CbGdCrCtD
Bosutinib—Renal failure—Doxorubicin—liver cancer	0.00011	0.00206	CcSEcCtD
Bosutinib—Hepatitis—Epirubicin—liver cancer	0.000108	0.00203	CcSEcCtD
Bosutinib—Urinary tract disorder—Epirubicin—liver cancer	0.000107	0.00201	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—liver cancer	0.000107	0.002	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—liver cancer	0.000106	0.002	CcSEcCtD
Bosutinib—Urethral disorder—Epirubicin—liver cancer	0.000106	0.00199	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—liver cancer	0.000105	0.00198	CcSEcCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—liver cancer	0.000105	0.0468	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—liver cancer	0.000105	0.0468	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—liver cancer	0.000105	0.0468	CbGdCrCtD
Bosutinib—Agranulocytosis—Doxorubicin—liver cancer	0.000104	0.00196	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—liver cancer	0.000102	0.00192	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—liver cancer	0.000102	0.0454	CbGdCrCtD
Bosutinib—Tinnitus—Epirubicin—liver cancer	0.000101	0.0019	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—liver cancer	0.0001	0.00189	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—liver cancer	0.0001	0.00188	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—liver cancer	9.88e-05	0.00186	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—liver cancer	9.86e-05	0.00185	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—liver cancer	9.83e-05	0.00185	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—liver cancer	9.81e-05	0.00184	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—liver cancer	9.77e-05	0.00184	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—liver cancer	9.75e-05	0.0433	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—liver cancer	9.75e-05	0.0433	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—liver cancer	9.75e-05	0.0433	CbGdCrCtD
Bosutinib—Mediastinal disorder—Epirubicin—liver cancer	9.74e-05	0.00183	CcSEcCtD
Bosutinib—Erythema multiforme—Doxorubicin—liver cancer	9.46e-05	0.00178	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—liver cancer	9.41e-05	0.00177	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—liver cancer	9.33e-05	0.00175	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—liver cancer	9.28e-05	0.00175	CcSEcCtD
Bosutinib—Dysgeusia—Epirubicin—liver cancer	9.22e-05	0.00173	CcSEcCtD
Bosutinib—Back pain—Epirubicin—liver cancer	9.1e-05	0.00171	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—liver cancer	9.04e-05	0.0017	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—liver cancer	9.02e-05	0.0017	CcSEcCtD
Bosutinib—ABCB1—embryo—liver cancer	9e-05	0.00248	CbGeAlD
Bosutinib—Ill-defined disorder—Epirubicin—liver cancer	8.73e-05	0.00164	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—liver cancer	8.71e-05	0.00164	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—liver cancer	8.7e-05	0.00164	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—liver cancer	8.53e-05	0.0016	CcSEcCtD
Bosutinib—Malaise—Epirubicin—liver cancer	8.49e-05	0.0016	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—liver cancer	8.43e-05	0.00158	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—liver cancer	8.42e-05	0.00158	CcSEcCtD
Bosutinib—Cough—Epirubicin—liver cancer	8.21e-05	0.00154	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—liver cancer	8.08e-05	0.00152	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—liver cancer	8.05e-05	0.00151	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—liver cancer	8.01e-05	0.00151	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—liver cancer	8.01e-05	0.00151	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—liver cancer	8.01e-05	0.00151	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	7.96e-05	0.0015	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—liver cancer	7.92e-05	0.00149	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—liver cancer	7.85e-05	0.00148	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—liver cancer	7.8e-05	0.00147	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—liver cancer	7.68e-05	0.00144	CcSEcCtD
Bosutinib—Oedema—Epirubicin—liver cancer	7.68e-05	0.00144	CcSEcCtD
Bosutinib—Infection—Epirubicin—liver cancer	7.63e-05	0.00144	CcSEcCtD
Bosutinib—Cough—Doxorubicin—liver cancer	7.6e-05	0.00143	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—liver cancer	7.53e-05	0.00142	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—liver cancer	7.52e-05	0.00141	CcSEcCtD
Bosutinib—Skin disorder—Epirubicin—liver cancer	7.46e-05	0.0014	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—liver cancer	7.41e-05	0.00139	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—liver cancer	7.41e-05	0.00139	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—liver cancer	7.41e-05	0.00139	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	7.36e-05	0.00138	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—liver cancer	7.33e-05	0.00138	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—liver cancer	7.11e-05	0.00134	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—liver cancer	7.11e-05	0.00134	CcSEcCtD
Bosutinib—Infection—Doxorubicin—liver cancer	7.06e-05	0.00133	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—liver cancer	7e-05	0.00132	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—liver cancer	6.97e-05	0.00131	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—liver cancer	6.96e-05	0.00131	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—liver cancer	6.9e-05	0.0013	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—liver cancer	6.85e-05	0.00129	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—liver cancer	6.68e-05	0.00126	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—liver cancer	6.63e-05	0.00125	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—liver cancer	6.62e-05	0.00125	CcSEcCtD
Bosutinib—Pain—Epirubicin—liver cancer	6.57e-05	0.00124	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—liver cancer	6.48e-05	0.00122	CcSEcCtD
Bosutinib—Dyspnoea—Doxorubicin—liver cancer	6.34e-05	0.00119	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—liver cancer	6.33e-05	0.00119	CcSEcCtD
Bosutinib—Gastrointestinal pain—Epirubicin—liver cancer	6.28e-05	0.00118	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—liver cancer	6.18e-05	0.00116	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—liver cancer	6.14e-05	0.00115	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—liver cancer	6.13e-05	0.00115	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—liver cancer	6.1e-05	0.00115	CcSEcCtD
Bosutinib—Pain—Doxorubicin—liver cancer	6.08e-05	0.00114	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—liver cancer	6.07e-05	0.00114	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—liver cancer	6.07e-05	0.00114	CcSEcCtD
Bosutinib—CYP3A4—liver—liver cancer	5.88e-05	0.00162	CbGeAlD
Bosutinib—Feeling abnormal—Doxorubicin—liver cancer	5.86e-05	0.0011	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—liver cancer	5.81e-05	0.00109	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—liver cancer	5.65e-05	0.00106	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—liver cancer	5.62e-05	0.00106	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—liver cancer	5.62e-05	0.00106	CcSEcCtD
Bosutinib—Asthenia—Epirubicin—liver cancer	5.51e-05	0.00104	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—liver cancer	5.43e-05	0.00102	CcSEcCtD
Bosutinib—Diarrhoea—Epirubicin—liver cancer	5.26e-05	0.000988	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—liver cancer	5.1e-05	0.000959	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—liver cancer	5.08e-05	0.000955	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—liver cancer	5.03e-05	0.000946	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—liver cancer	4.88e-05	0.000919	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—liver cancer	4.86e-05	0.000915	CcSEcCtD
Bosutinib—Rash—Epirubicin—liver cancer	4.84e-05	0.000911	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—liver cancer	4.84e-05	0.00091	CcSEcCtD
Bosutinib—Headache—Epirubicin—liver cancer	4.81e-05	0.000905	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—liver cancer	4.7e-05	0.000884	CcSEcCtD
Bosutinib—Nausea—Epirubicin—liver cancer	4.56e-05	0.000858	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—liver cancer	4.52e-05	0.00085	CcSEcCtD
Bosutinib—Rash—Doxorubicin—liver cancer	4.48e-05	0.000843	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—liver cancer	4.48e-05	0.000842	CcSEcCtD
Bosutinib—Headache—Doxorubicin—liver cancer	4.45e-05	0.000837	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—liver cancer	4.22e-05	0.000794	CcSEcCtD
Bosutinib—ABCB1—liver—liver cancer	4.16e-05	0.00115	CbGeAlD
Bosutinib—FYN—Immune System—HRAS—liver cancer	3.83e-07	2.79e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—liver cancer	3.83e-07	2.79e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PIK3CA—liver cancer	3.82e-07	2.78e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—liver cancer	3.82e-07	2.78e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—liver cancer	3.82e-07	2.78e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—liver cancer	3.82e-07	2.78e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP1A1—liver cancer	3.82e-07	2.78e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—liver cancer	3.81e-07	2.77e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—liver cancer	3.8e-07	2.77e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CDKN1A—liver cancer	3.8e-07	2.77e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PIK3CA—liver cancer	3.8e-07	2.77e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—liver cancer	3.8e-07	2.76e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—liver cancer	3.79e-07	2.76e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MTOR—liver cancer	3.79e-07	2.76e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CB—liver cancer	3.79e-07	2.76e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CDKN1A—liver cancer	3.78e-07	2.75e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK8—liver cancer	3.77e-07	2.74e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—liver cancer	3.76e-07	2.74e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—liver cancer	3.76e-07	2.74e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—liver cancer	3.75e-07	2.73e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—liver cancer	3.75e-07	2.73e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RAF1—liver cancer	3.75e-07	2.73e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—liver cancer	3.74e-07	2.72e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—liver cancer	3.72e-07	2.71e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CD—liver cancer	3.71e-07	2.7e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK8—liver cancer	3.71e-07	2.7e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—liver cancer	3.71e-07	2.7e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—liver cancer	3.7e-07	2.69e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK8—liver cancer	3.69e-07	2.69e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—liver cancer	3.68e-07	2.68e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—liver cancer	3.68e-07	2.68e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SERPINE1—liver cancer	3.67e-07	2.67e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—liver cancer	3.67e-07	2.67e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—liver cancer	3.67e-07	2.67e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MTOR—liver cancer	3.66e-07	2.66e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CB—liver cancer	3.66e-07	2.66e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—liver cancer	3.65e-07	2.66e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—liver cancer	3.65e-07	2.65e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—liver cancer	3.65e-07	2.65e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—liver cancer	3.64e-07	2.65e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—liver cancer	3.62e-07	2.64e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—liver cancer	3.61e-07	2.63e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—liver cancer	3.6e-07	2.62e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—liver cancer	3.6e-07	2.62e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—liver cancer	3.6e-07	2.62e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PSMD10—liver cancer	3.58e-07	2.6e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PSMA4—liver cancer	3.58e-07	2.6e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—liver cancer	3.58e-07	2.6e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—liver cancer	3.58e-07	2.6e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—liver cancer	3.57e-07	2.6e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1B—liver cancer	3.56e-07	2.59e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—liver cancer	3.56e-07	2.59e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—liver cancer	3.56e-07	2.59e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—liver cancer	3.54e-07	2.58e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—liver cancer	3.54e-07	2.57e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—liver cancer	3.53e-07	2.57e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—liver cancer	3.52e-07	2.56e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—liver cancer	3.52e-07	2.56e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—liver cancer	3.52e-07	2.56e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—liver cancer	3.52e-07	2.56e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—liver cancer	3.51e-07	2.56e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—liver cancer	3.51e-07	2.55e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARA—liver cancer	3.49e-07	2.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—liver cancer	3.49e-07	2.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—liver cancer	3.48e-07	2.54e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—liver cancer	3.48e-07	2.53e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GOT2—liver cancer	3.48e-07	2.53e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—liver cancer	3.47e-07	2.52e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—liver cancer	3.46e-07	2.52e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—liver cancer	3.46e-07	2.52e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—liver cancer	3.45e-07	2.51e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—liver cancer	3.45e-07	2.51e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—liver cancer	3.44e-07	2.5e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1B—liver cancer	3.43e-07	2.5e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—liver cancer	3.43e-07	2.5e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—liver cancer	3.42e-07	2.49e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—liver cancer	3.42e-07	2.49e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—liver cancer	3.41e-07	2.48e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—liver cancer	3.4e-07	2.47e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—liver cancer	3.39e-07	2.47e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—liver cancer	3.39e-07	2.47e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—JUN—liver cancer	3.39e-07	2.47e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—liver cancer	3.39e-07	2.46e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—liver cancer	3.38e-07	2.46e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—liver cancer	3.38e-07	2.46e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—liver cancer	3.37e-07	2.46e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—liver cancer	3.37e-07	2.45e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—liver cancer	3.36e-07	2.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—liver cancer	3.36e-07	2.45e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—liver cancer	3.36e-07	2.45e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—liver cancer	3.36e-07	2.44e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—liver cancer	3.35e-07	2.44e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—liver cancer	3.35e-07	2.44e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—liver cancer	3.34e-07	2.43e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—liver cancer	3.32e-07	2.42e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—liver cancer	3.32e-07	2.42e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—liver cancer	3.32e-07	2.42e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RAF1—liver cancer	3.32e-07	2.41e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—liver cancer	3.31e-07	2.41e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—liver cancer	3.31e-07	2.41e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—liver cancer	3.3e-07	2.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—liver cancer	3.3e-07	2.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1A—liver cancer	3.29e-07	2.39e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—liver cancer	3.27e-07	2.38e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—liver cancer	3.27e-07	2.38e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP2E1—liver cancer	3.27e-07	2.38e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—liver cancer	3.27e-07	2.38e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—JUN—liver cancer	3.27e-07	2.38e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—liver cancer	3.26e-07	2.38e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—liver cancer	3.26e-07	2.37e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—liver cancer	3.24e-07	2.36e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—liver cancer	3.24e-07	2.36e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MTOR—liver cancer	3.24e-07	2.36e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CB—liver cancer	3.24e-07	2.36e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—liver cancer	3.23e-07	2.35e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK8—liver cancer	3.21e-07	2.33e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—liver cancer	3.2e-07	2.33e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—liver cancer	3.2e-07	2.33e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—liver cancer	3.2e-07	2.33e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—liver cancer	3.2e-07	2.33e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—liver cancer	3.19e-07	2.32e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—liver cancer	3.18e-07	2.32e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—liver cancer	3.18e-07	2.31e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—liver cancer	3.17e-07	2.31e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1A—liver cancer	3.17e-07	2.31e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—liver cancer	3.15e-07	2.3e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—liver cancer	3.15e-07	2.29e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—liver cancer	3.15e-07	2.29e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—liver cancer	3.14e-07	2.28e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—liver cancer	3.13e-07	2.28e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—liver cancer	3.12e-07	2.27e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—liver cancer	3.11e-07	2.26e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—liver cancer	3.1e-07	2.26e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK8—liver cancer	3.09e-07	2.25e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—liver cancer	3.07e-07	2.23e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—liver cancer	3.06e-07	2.23e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYCS—liver cancer	3.06e-07	2.23e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—liver cancer	3.06e-07	2.22e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—liver cancer	3.05e-07	2.22e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—liver cancer	3.05e-07	2.22e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1B—liver cancer	3.04e-07	2.21e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—liver cancer	3.02e-07	2.2e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—liver cancer	3.02e-07	2.2e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—liver cancer	3.01e-07	2.19e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GGT1—liver cancer	3e-07	2.19e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GOT1—liver cancer	3e-07	2.19e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—liver cancer	2.99e-07	2.18e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—liver cancer	2.98e-07	2.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—liver cancer	2.98e-07	2.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—liver cancer	2.97e-07	2.16e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—liver cancer	2.96e-07	2.16e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—liver cancer	2.96e-07	2.15e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—liver cancer	2.94e-07	2.14e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—liver cancer	2.93e-07	2.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—liver cancer	2.92e-07	2.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—liver cancer	2.92e-07	2.13e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—liver cancer	2.91e-07	2.12e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—liver cancer	2.9e-07	2.11e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—liver cancer	2.9e-07	2.11e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JUN—liver cancer	2.89e-07	2.11e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—liver cancer	2.88e-07	2.1e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—liver cancer	2.88e-07	2.1e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—liver cancer	2.87e-07	2.09e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—liver cancer	2.85e-07	2.08e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—liver cancer	2.85e-07	2.07e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—liver cancer	2.83e-07	2.06e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—liver cancer	2.83e-07	2.06e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—liver cancer	2.82e-07	2.06e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—liver cancer	2.82e-07	2.05e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—liver cancer	2.82e-07	2.05e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—liver cancer	2.82e-07	2.05e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—liver cancer	2.81e-07	2.05e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1A—liver cancer	2.8e-07	2.04e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—liver cancer	2.78e-07	2.02e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—liver cancer	2.75e-07	2e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK8—liver cancer	2.74e-07	1.99e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—liver cancer	2.72e-07	1.98e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—liver cancer	2.72e-07	1.98e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—liver cancer	2.72e-07	1.98e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—liver cancer	2.7e-07	1.97e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—liver cancer	2.7e-07	1.96e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—liver cancer	2.7e-07	1.96e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—liver cancer	2.69e-07	1.96e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—liver cancer	2.68e-07	1.95e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—liver cancer	2.66e-07	1.94e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMOX1—liver cancer	2.66e-07	1.94e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—liver cancer	2.66e-07	1.94e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—liver cancer	2.63e-07	1.92e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—liver cancer	2.63e-07	1.91e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CD—liver cancer	2.63e-07	1.91e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—liver cancer	2.63e-07	1.91e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—liver cancer	2.62e-07	1.91e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—liver cancer	2.61e-07	1.9e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—liver cancer	2.6e-07	1.89e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—liver cancer	2.59e-07	1.89e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—liver cancer	2.59e-07	1.89e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—liver cancer	2.58e-07	1.88e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—liver cancer	2.57e-07	1.87e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—liver cancer	2.53e-07	1.84e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—liver cancer	2.52e-07	1.83e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—liver cancer	2.52e-07	1.83e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—liver cancer	2.52e-07	1.83e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—liver cancer	2.5e-07	1.82e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—liver cancer	2.5e-07	1.82e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—liver cancer	2.49e-07	1.81e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—liver cancer	2.48e-07	1.81e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—liver cancer	2.48e-07	1.8e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—liver cancer	2.46e-07	1.79e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—liver cancer	2.46e-07	1.79e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—liver cancer	2.43e-07	1.77e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—liver cancer	2.41e-07	1.75e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—liver cancer	2.37e-07	1.73e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—liver cancer	2.36e-07	1.72e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1A1—liver cancer	2.35e-07	1.71e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—liver cancer	2.33e-07	1.69e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—liver cancer	2.32e-07	1.69e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—liver cancer	2.32e-07	1.69e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—liver cancer	2.31e-07	1.68e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—liver cancer	2.3e-07	1.68e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CB—liver cancer	2.29e-07	1.67e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—liver cancer	2.27e-07	1.65e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—liver cancer	2.24e-07	1.63e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—liver cancer	2.23e-07	1.62e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—liver cancer	2.22e-07	1.62e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—liver cancer	2.19e-07	1.6e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—liver cancer	2.19e-07	1.59e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—liver cancer	2.18e-07	1.58e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—liver cancer	2.16e-07	1.57e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARA—liver cancer	2.15e-07	1.57e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—liver cancer	2.15e-07	1.56e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—liver cancer	2.14e-07	1.56e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—liver cancer	2.06e-07	1.5e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—liver cancer	2.05e-07	1.49e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—liver cancer	1.97e-07	1.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—liver cancer	1.97e-07	1.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—liver cancer	1.91e-07	1.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—liver cancer	1.89e-07	1.38e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—liver cancer	1.84e-07	1.34e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—liver cancer	1.83e-07	1.33e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—liver cancer	1.82e-07	1.33e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—liver cancer	1.78e-07	1.29e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—liver cancer	1.75e-07	1.27e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CD—liver cancer	1.62e-07	1.18e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—liver cancer	1.61e-07	1.17e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—liver cancer	1.6e-07	1.16e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CB—liver cancer	1.41e-07	1.03e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—liver cancer	1.4e-07	1.02e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—liver cancer	1.14e-07	8.3e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—liver cancer	8.6e-08	6.26e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—liver cancer	7.03e-08	5.12e-07	CbGpPWpGaD
